Intensification of antihyperglycemic therapy among patients with incident diabetes: A Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study

Marsha A. Raebel, Jennifer L. Ellis, Emily B. Schroeder, Stanley Xu, Patrick J. O'Connor, Jodi B. Segal, Melissa G. Butler, Julie A. Schmittdiel, H. Lester Kirchner, Glenn K. Goodrich, Jean M. Lawrence, Gregory A. Nichols, Katherine M. Newton, Ram D. Pathak, John F. Steiner

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Purpose: Antihyperglycemic medication intensification practices among patients with incident diabetes are incompletely understood. We characterized the first intensification the year after oral antihyperglycemic medication initiation among incident diabetes patients. Methods: This retrospective cohort study across 11 US health systems included adults identified with incident diabetes between 2005 and 2009 who started oral antihyperglycemic monotherapy or combination therapy within 6months after diabetes identification. We determined intensification, defined as increased index medication dosage, addition of another oral medication, or switch to/addition of insulin 31-365days after initial antihyperglycemic dispensing. Cox regression was used to assess intensification for patient, temporal, and system covariates, adjusting for glycosylated hemoglobin (HbA1c) as a time-dependent variable. Results: Among 41233 patients, 33.5% and 45.3% had treatment intensified within 6 and 12months, respectively. This first intensification was most often with increased index medication dosage (78%), least often with insulin (<1%). HbA1c% was strongly associated with intensification (adjusted hazard ratios [HR] 1.59, 3.62, 4.44, and 5.52 for HbA1c 6.5% to <7%, 7% to <7.5%, 7.5 to <8%, and ≥8%, respectively, all P<0.001, compared with HbA1c<6.5%). In patients initially on monotherapy, age modified the HbA1c effect: at HbA1c<7%, the HR differed little between middle-aged and older patients; at HbA1c≥7%, the HR decreased with older age (e.g., age 40-49years and HbA1c≥8%: HR 8.14; age≥80years and HbA1c≥8%: HR 4.44; compared with age≥80years and HbA1c<6.5%). Within 1year, 84.3% achieved HbA1c<8%; 65.1% achieved HbA1c<7%. Conclusions: Clinicians appear to be applying treatment intensification guidelines and individualizing therapy by considering patient age, achieving glycemic control among most incident diabetes patients.

Original languageEnglish (US)
Pages (from-to)699-710
Number of pages12
JournalPharmacoepidemiology and Drug Safety
Issue number7
StatePublished - Jul 2014


  • Adult
  • Antihyperglycemic medication
  • Glycosylated hemoglobin
  • Incident diabetes
  • Metformin
  • Pharmacoepidemiology
  • Sulfonylurea
  • Treatment intensification

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)


Dive into the research topics of 'Intensification of antihyperglycemic therapy among patients with incident diabetes: A Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study'. Together they form a unique fingerprint.

Cite this